Wolfe Research on Protagonist Therapeutics (PTGX): 'We forecast peak sales of $2.9B in 2036'
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $225.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)